Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) and may include paid advertising.
- ONC010 is being developed for biomarker-selected cancers, aligning with the growing shift toward precision medicine
- The company is currently advancing ONC010 through manufacturing, and IND-enabling development programs
- Onco-Innovations combines targeted therapeutics, nanoparticle drug delivery, and AI-native discovery to address treatment-resistant cancers
Cancer treatment is undergoing one of its most significant transformations in decades. Rather than relying on the traditional “one drug fits all” approach, oncology is increasingly embracing precision medicine. This strategy uses genomic testing and biomarker analysis to identify patients most likely to benefit from specific therapies. By matching treatments to the unique biology of a patient’s tumor, physicians can improve outcomes while reducing unnecessary exposure to therapies that may offer limited clinical benefit (ibn.fm/tNpcJ).
Drug developers are increasingly designing therapies for biomarker-defined patient populations, while regulations, clinicians, and healthcare systems continue to expand the use of genomic testing to guide treatment decisions. As precision oncology becomes the new standard of care, developers capable of creating targeted therapies for genetically defined cancers are positioned to address one of oncology’s fastest-growing markets.
Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) is aligning its development strategy with this industry transformation through ONC010, its lead nanoparticle-encapsulated Polynucleotide kinase-phosphatase (“PNKP”) inhibitor. Designed for biomarker-selected cancers, ONC010 targets tumors that may be particularly susceptible to DNA Damage Response (“DDR”) therapies. The program combines a novel therapeutic target with nanoparticle drug delivery and an AI-native discovery platform, positioning Onco-Innovations within one of oncology’s most promising areas of innovation.
As the company advances toward First-in-Human clinical studies, it is building the scientific and manufacturing foundation supporting ONC010. Recent milestones include the initiation of polymer process development and analytical characterization activities with Nanosoft Polymers, designed to establish a robust, scalable, and reproducible manufacturing platform (ibn.fm/ztsui). According to CEOThomas O’Shaughnessy, “The initiation of this work with Nanosoft represents an important step in strengthening the manufacturing and formulation foundation of ONC010.” He noted that the collaboration is helping establish “a more scalable and reproducible pathway toward future GMP manufacturing and clinical development.”
In parallel, Onco-Innovations has initiated three-species hepatocyte and liver microsome metabolism studies through Nucro-Technics, a key component of its integrated IND-enabling development strategy (ibn.fm/0UaW4). These studies are intended to characterize how ONC010 is metabolized across human, dog, and rat systems, generating data capable of supporting pharmacokinetic modeling, dose selection, toxicology planning, and future regulatory submissions. Together with ongoing chemistry, manufacturing and controls (“CMC”) activities, initiatives are designed to reduce development risk while preparing ONC010 for clinical evaluation.
Onco-Innovations operates at the intersection of precision medicine, targeted oncology, advanced drug delivery, and artificial intelligence. Its integrated development ecosystem combines proprietary PNKP inhibitors, nanoparticle formulation technologies, specialized manufacturing expertise, and AI-driven discovery tools to speed up the development of therapies for biomarker-selected cancers.
For more information, visit https://oncoinnovations.com.
NOTE TO INVESTORS: The latest news and updates relating to ONNVF are available in the company’s newsroom at ibn.fm/ONNVF
